Cabozantinib和Everolimus晚期肾细胞癌。

文章的细节

引用

复制到剪贴板

Choueiri TK, Escudier B, Powles T,美因威林PN,里BI, Donskov F,锤子H, Hutson TE, Lee JL Peltola K,罗斯BJ, Bjarnason GA, Geczi L, Keam B, Maroto P,亨DY, Schmidinger M, Kantoff PW, Borgman-Hagey,埃塞尔C, Scheffold C,施瓦布通用,Tannir NM, Motzer RJ

Cabozantinib和Everolimus晚期肾细胞癌。

郑传经地中海J。2015年11月5日,373(19):1814 - 23所示。doi: 10.1056 / NEJMoa1510016。Epub 2015年9月25日。

PubMed ID

26406150 (在PubMed

]

文摘

背景:Cabozantinib是口服的小分子酪氨酸激酶抑制剂,目标血管内皮生长因子受体(VEGFR)以及满足妳的每一个都已经涉及到转移性肾细胞癌的病理学或抗血管新生药物发展的阻力。一随机、非盲、3期临床试验评估cabozantinib的功效,作为与everolimus相比,肾细胞癌患者进展VEGFR-targeted治疗后。方法:我们随机选取了658名患者接受cabozantinib 60毫克的剂量每日或everolimus每天10毫克的剂量。主要终点是无进展生存。次要疗效终点是总体存活率和客观缓解率。结果:平均无进展生存期是7.4个月和everolimus cabozantinib和3.8个月。恶化或死亡的速度降低了42%与cabozantinib everolimus(风险比,0.58;95%可信区间[CI] 0.45到0.75;P < 0.001)。客观缓解率为21%,与everolimus cabozantinib和5% (P < 0.001)。 A planned interim analysis showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P=0.005) but did not cross the significance boundary for the interim analysis. Adverse events were managed with dose reductions; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus. Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus. CONCLUSIONS: Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Cabozantinib